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Short term outcomes of the use of high dose
intravenous methylprednisolone for acute optic
neuritis in a central Anatolian population
Aim: To describe the clinical characteristics and outcome of optic neuritis (ON) cases treated with
high dose intravenous methylprednisolone (IVMP) in a tertiary referral clinic in Ankara, Turkey.
Methods: Consecutive patients in the past 5 years with acute isolated ON, who were treated with
IVMP and had a follow–up of at least 3 months, were reviewed. Symptoms and findings, results of
brain magnetic resonance imaging (MRI), etiologies, visual outcomes, and side effects of the
treatment were evaluated.
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Results: Etiological causes could be elicited in 57 (85.1%) of 67 patients; the most common of which
was multiple sclerosis (MS). At least 1 MS–compatible white matter lesion was present on brain MRI
in 31 (46.3%) patients. Seventeen (63.0%) of those with clinically definite MS (CDMS) had ON as the
initial feature of their disease (25.4% of all patients). Early treatment was associated with better short
term visual outcomes. Diagnosis of MS was more possible in patients with retrobulbar neuritis and
MS patients achieved better short term visual outcomes than non-MS patients with IVMP.
Conclusion: The majority of our cases were associated with MS and evidence from our study
confirmed the short term benefit of the standard therapy in our population.
Key words: Acute optic neuritis, high dose intravenous methylprednisolone, multiple sclerosis

Orta Anadolu popülasyonunda intravenöz yüksek doz metil
prednizolon ile akut optik nevrit tedavisinin kısa dönem sonuçları
Amaç: Ankara’daki üçüncü basamak tedavi merkezinde yüksek doz intravenöz metilprednizolon
(İVMP) ile tedavi edilen optik nevrit (ON) hastaların klinik özelliklerini ve sonuçlarını tanımlamak.
Yöntem ve gereç: Geçmiş 5 yıl içinde akut izole ON nedeniyle İVMP tedavisi uygulanan ve en az 3
aylık takibi bulunan hastalar gözden geçirildi. Semptomlar ve bulgular, kranial manyetik rezonans
görüntüleme (MRG) sonuçları, etyolojik nedenler, görme sonuçları ve tedavinin yan etkileri
değerlendirildi.
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Bulgular: Çalışma kriterlerine uyan 67 hastanın 57sinde (% 85,1) etyolojik neden tespit edilebildi.
En sık karşılaşılan etyolojik neden multipl sklerozdu (MS). Otuz bir hastanın (% 46,3) beyin
MRG’sinde en az 1 adet MS ile uyumlu beyaz cevher lezyonu tespit edildi. Kesin MS tanısı konanların
17’sinde (% 63,0) ON başlangıç bulgusuydu (tüm hastaların % 25,4’ü). Erken tedavi, erken dönem
görme prognozunu olumlu etkiledi. Retrobulber nevrit tanısı ve İVMP tedavisi sonrası daha iyi
görme keskinlikleri MS ile ilişkili bulundu.
Sonuç: Hastalarımızın büyük bir çoğunluğu MS ile uyumluydu ve çalışmamızın sonuçları standart
tedavinin kısa dönem faydalarını doğruladı.
Anahtar sözcükler: Akut optik nevrit, yüksek doz intravenöz metilprednizolon, multipl skleroz

Introduction
Optic neuropathy is a wide definition that comprises primary demyelination
or non-demyelinating disease of optic nerve. The term optic neuritis (ON) is
usually used for primary demyelinating events, such as the optic neuropathy
associated with multiple sclerosis or idiopathic conditions (1). The most common
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cause is optic nerve demyelination and the association
between ON and demyelinating disease is well
established. It commonly occurs as an isolated
neurological finding and may represent a forme fruste
of multiple sclerosis (MS) (2,3).
Studies related to ON have been ongoing in
western countries. In USA, the optic neuritis
treatment trial (ONTT) is a randomized, multi
centered, placebo-controlled clinical trial (3,4). Also,
there are some reports describing the epidemiological
and clinical features of ON from different Asian
countries (5-8). However, we are not aware of any
longitudinal studies in Middle–Eastern countries, and
there is only one similar study from Turkey in the
literature (9).
In the present study, we aimed to describe the
clinical features, etiology and visual outcomes of
patients with ON who were treated with high dose
intravenous methylprednisolone (IVMP) in our
tertiary eye clinic in Ankara, Turkey.
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single dose or in 4 divided doses for 3 days. Pulse rate
and blood pressure were monitored during
intravenous infusion therapy. Serum electrolytes and
blood sugar (fasting and postprandial) were evaluated
before and after treatment. Thereafter, therapy was
continued with an oral prednisolone equivalent dose
of 1mg/kg/day for 11 days and then the dose was
tapered to be discontinued in the third week. Adverse
effects of the treatment were recorded during and
after hospital stay.
Brain MRI was performed before or during
hospital stay. Other laboratory tests and consultations
were carried out as needed. Aforementioned
ophthalmic parameters were evaluated daily during
the period of intravenous treatment. Afterwards,
patients were examined during week 1, 4, and 12.
From then on, at least 1 final follow-up visit was
scheduled.
Descriptive statistics were used for evaluating the
data. Statistical analyses were carried out using SPSS
9.0 with Pearson Chi-Square Test and Fisher’s Exact
Test.

Materials and methods
This study was a retrospective, observational case
series involving 67 patients with acute
isolated optic neuritis (ON) who were
hospitalized, evaluated with brain magnetic resonance
imaging (MRI), treated with high dose intravenous
methylprednisolone (IVMP), and followed for at least
3 months. Clinical data were abstracted from the last
5 years’ patient charts of the Neuro-ophthalmology
Department.
Symptoms and a complete neuro-ophthalmic
examination were recorded. Best corrected distance
visual acuity (VA) (Snellen’s chart), color vision (CV)
(Ishihara’s color vision plates), relative afferent
pupillary defect (RAPD) (swinging flashlight test),
fundoscopy (dilated pupil-90 D lens), and visual fields
(VF) (Humphrey ® Field Analyzer or confrontation)
were evaluated. Decision for treating each patient with
IVMP was made solely on clinical basis; taking into
account the visual, medical, and social conditions of
the patient at the initial examination. Therapy was
started immediately after a total blood count, blood
chemistry test, and a chest X-ray. All patients were
hospitalized and received IVMP 1000 mg/day as a
902

Results
Seventy six eyes of 67 patients were evaluated. Of
the 67 patients, 16 (23.9%) were male and 51 (76.1%)
were female. Mean age was 29.0 ± 10.8 years (7 to 51
years). Demographic features and clinical summary
of the patients are summarized in Tables 1 and 2.
Table 1. Demographic features of the patients.
Sex

No of patients (%)

Mean age

Female

51 (76.1 )

27.5 ± 11.8

Male

16 (23.9 )

29.4 ± 10.5

Table 2. Types of involvement of optic nerve head.
No of patients (%)

Unilateral
Bilateral
Total

Anterior

Retrobulbar

Total

12
8

46
1

58
9

20 (29.9)

47 (70.1)

67 (100)
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Twenty seven of our patients (40.3%) had pain
with ocular movements and retrobulbar or
supraciliary discomfort before or during visual loss.
Among these; 17 were diagnosed with MS (63.0%).
Of patients who did not complain of pain upon eye
movements, 42.5% were diagnosed with MS. The
difference was obvious but not statistically significant
(P = 0.060). Pain was relieved in the first 24 h in all
patients during IVMP therapy.
Retrobulbar neuritis was diagnosed in 47 patients
(70.1%) in our study group. Among these; 28 were
diagnosed with MS. Of other 20 patients with optic
disc swelling (papillitis), 6 were diagnosed with MS.
This difference was statistically significant (P = 0.034).
At the initial examination, 4 eyes (5.3%) had no
light perception, 54 eyes (71.0%) had light perception
to finger counting vision. Sixty eight (89.5%) of the
affected eyes had no CV at presentation. The best CV
was 4/12. Confrontation VFs demonstrated diffuse
central depression in 70 eyes (92.1%). Automatated
perimetry revealed other types of VF defects in 6 eyes
(7.9%), which included para central in 3, arcuate in 2,
and altitudinal in 1. A positive RAPD was recorded
in 58 charts.
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Thirty one patients (46.3%) demonstrated MScompatible plaques on the brain MRI. In 26 of these,
there were more than 2 plaques. Increased signal
consistent with optic nerve demyelination was also
detected in 3 MS patients. In 5 patients (7.4%),
multiple plaques incompatible with MS were present.
These were diagnosed with central nervous system
vasculitis, SLE, mitral valve prolapsus, and brain
metastasis. Optic nerve demyelination was confirmed
with orbital MRI in 5 unilateral cases with normal
brain MRI (7.4%). Additionally, pan sinusitis was
detected in 5 patients. MRI findings are summarized
in Table 3.
Etiological causes could be elicited in 57 patients
(85.1%) along with 10 patients (14.9%) who were
classified as idiopathic. MS was the most commonly
diagnosed disease. CDMS was present in 27 patients
(40.3%). Diagnosis of CDMS was present before the
ON attack in 10 and ON was the first attack of CDMS
in 17. This means that; 25.4% of all patients and 63.0%
of the CDMS patients had an ON attack as the
presenting feature of CDMS. An additional 7 patients
were considered as probable MS cases after
neurological consultation. Other etiologic factors

Table 3. Brain MRI findings of patients (MS: Multiple Sclerosis).

No of patients

%

Brain MRI findings
No of patients

46.28

26
2
3

MS related plaques
>2 plaques
2 plaques
1 plaque

5

7.46

3
1
1

Non-MS plaques
Vasculitis
Occlusive
Metastatic

5

7.46

Optic nerve demyelination
Normal brain MRI

5

7.46

Pansinusitis
Normal brain MRI

21

31.34

NORMAL

67

100

31

Total

903
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were found to be post-viral demyelination,
vasculitides, pan sinusitis, vaso-occlusive disease, and
brain metastasis (Table 4).
Time to treatment with IVMP from the first
symptom was 8.3 ± 6.7 days (range 1 to 30 days). Time
to treatment was 0-7 days in 39 patients (58.2%) and
8 or more days in 28 patients (41.8%). Final visual
acuity was better than 0.5 in 38 (97%) of the early
treated group and 21 (75%) in the late treated group.
This difference was statistically significant (P = 0.028).
Adverse effects of treatment were recorded in 14
patients (21.0%) during or after therapy. These were,
in decreasing frequency; sour taste in mouth, flushing
and fever (during infusion); nausea, vomiting and/or
stomach ache, insomnia, depression, crying episodes,
transient increase in blood sugar and hepatic enzymes
(shortly after infusion); and weight gain, back pain
and menstrual changes (during the course of oral
therapy). These side effects disappeared in a short
time period after tapering of steroids.

Table 4.

Patients were followed for a mean of 7.86 ± 8.29
months (range 3 to 48 months). VA recovered to
better than 0.5 at the end of the follow-up in 59 eyes
(77.7%). In this group with good visual outcome, 22
were diagnosed with MS. Of the patients who had less
than 0.5 VA at the end of follow-up, only 2 were
diagnosed with MS. This difference was statistically
significant (P = 0.017).
Thirty nine eyes (51.3%) regained full CV. Only 8
eyes (10.5%) remained totally color blind. VF testing
was performed in 69 eyes at the end of the study.
Persistent arcuate and para central field defects were
found in 24 patients (34.8%). Pre and post-treatment
visual functions of patients are summarized in Table
5. RAPD was not recorded in a number of patients
after therapy, therefore evaluation was not possible.
At the last examination, 33 patients (49.3%) had
normal-appearing optic discs and 34 patients (50.7%)
had temporal optic atrophy. Two patients with CDMS
had recurrent attacks in contra lateral eyes during
follow-up.

Etiological causes (CDMS: Clinically Definite Multiple Sclerosis, Dx: Diagnosis, CNS:
Central Nervous System, SLE: Systemic Lupus Erythematosus).

Etiology (No of patients)

%
50.7

Idiopathic

10

14.9

Postviral

8

11.9

8

11.9

Pan-sinusitis

5

7.4

Occlusive

1

1.6

Brain metastasis

1

1.6

Total

67

100

Vasculitis

CDMS present (10)
CDMS new Dx(17)
Probable MS (7)

Number
34

MS related
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CNS vasculitis (2)
Retinal vasculitis (1)
SLE (3)
Autoimmune (1)
Behcet’s Disease (1)
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Pre and post-treatment visual statuses of patients (CV: Color Vision, CS: Central Scotoma, VF: Visual Field, VFD: Visual Field
Defect).
At the initial examination

After treatment

No of eyes

%

No of eyes

%

Visual acuity
0.1 ↓
0.1-0.5
0.5 ↑

58
17
1

76.3
22.4
1.3

Visual acuity
0.1 ↓
0.1-0.5
0.5 ↑

2
15
59

2.6
19.7
77.7

Color vision
No CV
1-6/12
7 -12/12

68
8
0

89.5
10.5
0

Color vision
No CV
1-6/12
7 -12/12

8
14
54

10.5
18.5
71.0

Visual field
CS
Other VFDs
Normal VF

70
6
0

92.1
7.9
0

Visual field
CS
Other VFDs
Normal VF

1
24
44

1.4
34.8
63.8

Discussion
We integrated all patients treated with high dose
IVMP into this retrospective study; however, our
patients were a heterogeneous group, which was
different from the patients studied in the ONTT and
other studies. The present study included children and
adults, unilateral and bilateral cases, first or second
attacks, people who had visual loss lasting longer than
7 days before the initiation of therapy, and people with
other diseases. We keep all differences in mind, but
still comparisons with ONTT and other studies help
us define the clinical characteristics and response to
treatment in our population.
Our local population, with a mean age of 29.0
years was slightly younger than the ONTT population
(mean age: 31.8). Excluding the 4 children younger
than 12 years, our population’s mean age rises to 30.3
years. A median age of 30.5 years is reported from
India, older median ages of 35.6 and 39.1 years are
reported in Asian populations (6-8). The median age
was 28 years in a Scandinavian study (10).
Seventy six percent of our patients were female.
This figure is 77% in ONTT and 62% in the
Scandinavian study (3,10). Women’s ratio is lower in
studies involving Indian (25%) and Asian (39%)
populations (6,8). Our population’s sex ratio
resembles the ONTT population in this respect. We
are not aware of any similar study involving
Mediterranean or Middle-eastern demographic.

Periocular pain exacerbated by ocular movements
in acute demyelinating optic neuropathy patients is
reported as 50% in an Asian population and nearly
90% in ONTT (3,6). This percentage includes all (MS
or non-MS) inflammatory optic neuropathies. Optic
nerve inflammation is thought to cause pain by
stimulating the trigeminal innervation of the optic
nerve sheath (2). Pain is one of the clinical features
associated with a higher risk of MS (11). Of our
patients, 40.3% had pain with ocular movements and
retrobulbar or supraciliary discomfort before or
during visual loss. MS was more often diagnosed in
patients who experienced retrobulbar or supraciliary
pain, but the difference did not reach statistical
significance (P = 0.060).
Normal appearing optic disc (retrobulbar optic
neuritis) is another feature linked to a higher risk of
MS (11). Retrobulbar ON is reported in 71% in the
Scandinavians, 66% of the ONTT group, and 35 % in
an Asian population sample (3,6,10). Retrobulbar
neuritis was diagnosed in 47 patients (70.1%) in our
study group. Among these, MS was more often
diagnosed compared to the patients with papillitis (P
= 0.034).
The third feature attributed to a higher risk of MS
is the low VA (less than 0.5) at presentation (3). All of
our patients except only 1 CDMS patient had VAs of
less than 0.5. Since we retrospectively analyzed
905
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patients who underwent IVMP therapy, evidently we
did not treat patients with good vision therefore we
cannot comment on VA at presentation.
After 6 months follow–up, the percent of eyes
regaining full VA was 62% in ONTT and 57% and
39% in Asian studies (6,8). We achieved full VA in 41
of 76 eyes (54%). When we look at the final VAs, it
appears that our MS patients had better visual
outcomes than non-MS patients. Patients who had a
final VA of at least 0.5 were more frequent in patients
diagnosed with MS when compared to non MS
patients (P = 0.017)
Color vision deficit was detected in all patients at
presentation. At the end of follow–up, 8 eyes (10.5%)
remained totally color blind. Mild CV abnormalities
were permanent in 48.7%. More patients mentioned
red desaturation and contrast sensitivity deficits,
which we did not document. In ONTT and other
studies, it was shown that even after maximal recovery
of visual function, a subtle CV abnormality was the
most common residual visual deficit (12).
The most common visual field defect at
presentation was diffuse central depression (92.1%).
This includes central and pericentral defects, because,
due to our patients’ low levels of VA, we mostly
evaluated VFs by confrontation. At the final visit,
34.8% of tested eyes had residual, mostly insignificant
VF defects. In ONTT, subtle VF defects persisted in
48% of patients (12).
It is reported that 40% to 70% of those who have
isolated optic neuritis, periventricular white matter
signal abnormalities are detected on MRI scans
(2,3,10). The development of CDMS is strongly
associated with the presence of 1 or more lesions on
the baseline MRI of the brain (11). Up to 50% of
patients with MS will develop ON and 20% of the
time, ON is the presenting sign of MS (1,2,10,11).
Abnormal brain MRI was obtained in 68.7% of our
patients. Thirty one (46.3%) demonstrated MScompatible demyelinating plaques. In a former
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Turkish study of MS patients, 53.3% of 68 patients
with CDMS had evidence of a previous ON attack
(13). In 63.3% of our patients diagnosed with CDMS,
ON attack was the presenting feature of the disease.
This percentage is noticeably high which implies that
the importance of obtaining brain MRI in the first
attack of ON in every patient is imperative.
Our treatment decision was only dependent on the
initial clinical evaluation; therefore, we did not wait
for any test results except routines to start treatment.
In the ONTT, typical features of acute demyelinating
ON were considered and less than 1.0% of patients
were misdiagnosed. We mostly diagnosed MS,
vasculitic diseases, and idiopathic or post viral
inflammations, in whom we started treatment without
thorough investigations. These can all be treated with
IVMP. However, we seem to have mistreated the
anterior ischemic optic neuropathy (AION) in cases
with mitral valve prolapsus and breast carcinoma
metastasis and we put these 2 patients under undue
risk since IVMP is controversial in the treatment of
AION.
Also, we did not respect the ONTT deadline of 7
days, and initiated treatment as late as 30 days. Time
to treatment was 0-7 days in 39 patients (58.2%) and
8 or more days in 28 patients (41.8%). Final visual
acuity was better in the early treated group (P =
0.028). This implies that we should not hesitate to treat
with IVMP when we think appropriate as soon as we
examine the patient. This is especially worth
consideration in countries like Turkey where people
may not have rapid access to the neuroophthalmologist.
Although our population sample and study
parameters were not exactly similar, considering the
high incidence of the CDMS diagnosis after ON and
the low incidence of side effects of this therapy, we
think that the ONTT guidelines can be used safely in
our population and we recommend high dose IVMP
with caution in patients with ON.
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